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consumables amount 0.84€ per preparation (0.48€ due to time
saving and 0.36€ linked to less use of consumables). For the case
of colorectal cancer standard chemotherapy regimen in adjuvant
(12 cycles) these savings could mean annually 10,080€ per 1,000
patients. CONCLUSION: The concentration solution, a new
presentation of oxaliplatin, has signiﬁcant advantages compared
with the traditional lyophilised powder. These advantages have
been measured as monetary savings linked to less preparation
time and use of consumables. In the future it would be of interest
to assess other advantages of concentrated solution chemothera-
pies over the more conventional ones like less errors of medica-
tion due to manipulation.
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OBJECTIVES: A recent randomized 2 ¥ 2 phase III trial com-
pared oral capecitabine + IV oxaliplatin (XELOX), IV 5-FU/LV/
oxaliplatin (FOLFOX-4), XELOX+bev, and FOLFOX-4+bev as
ﬁrst-line therapy for MCRC. FOLFOX-4 was the regulatory
control. XELOX was non-inferior to FOLFOX-4 for
progression-free survival, and bev-containing regimens were
superior to comparison arms. This economic analysis compared
expected costs in XELOX vs. FOLFOX-4 arms in an Italian
hospital setting from a payer and societal perspective.
METHODS: Direct medical and indirect cost estimates (for
patient time and travel) were compared. Resource use and
patient time were estimated based on trial data and protocols.
Data collected during the trial and used in the analysis were as
follows: no. of visits/duration of drug administration, central
venous access management, treatment of adverse events (AE)
including hospital days for treatment-related AEs and total hours
of ambulatory encounters. Unit costs were based on hospital
costs and other published sources. RESULTS: Total direct
medical cost estimates were higher for bi-weekly FOLFOX-4 vs.
3-weekly XELOX: €17,900 vs. €10,900. XELOX had higher
drug costs while FOLFOX-4 had higher drug administration
costs, with about 15 more visits on average per patient. Costs for
hospitalization and ambulatory encounters were slightly lower
for FOLFOX-4 (€500 vs. €800); other medications and venous
access were slightly higher for FOLFOX-4 (€5000 vs. €2000).
Similar patterns held for FOLFOX-4+bev vs. XELOX+bev (total
direct medical cost estimates €33,100 vs. €25,000). Indirect time
cost estimates were lower with XELOX due to fewer cycles and
visits: estimated savings range from €9,000–€11,000. CONCLU-
SION: XELOX is cost-saving from both payer and societal per-
spective in comparison to FOLFOX-4.
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OBJECTIVES: The objective of this study was to estimate Irish
speciﬁc costs for managing abnormal cervical conditions which
are required for cost-effectiveness analysis of prophylactic cervi-
cal cancer vaccination in Ireland. Methods: This was a retrospec-
tive study that collected resource utilisation and clinical outcome
data on 395 women attending four colposcopy clinics in Ireland.
Sampling was stratiﬁed to include 10%, 35%, 25%, 25% and
5% of women in the borderline, mild, moderate, severe and
cancer cytology groups respectively. Data were collected from the
date of referral until the latest treatment or the patient returned
to ‘normal’ cytology. Unit cost data, also collected during the
study, were applied to the utilisation data to estimate costs.
RESULTS: The mean age of all women with abnormal smears
was 31 years (range 18–68). The mean age of women with cancer
was 48 (range 23–68). The average cost of treating women who
initially had an abnormal smear but were subsequently observed
to be histologically negative without receiving treatment was
€317 (SD €147). The corresponding costs for women with CIN1,
CIN2 and CIN3 were €522 (SD €255), €673 (SD €237), and
€689 (SD €227) respectively. The average cost of treating invasive
cervical cancer was €10,449 (SD €4,952). The total cost of man-
aging abnormal cervical conditions was estimated at around €10
million per annum. CONCLUSION: Managing abnormal cervi-
cal conditions is expensive. Analysis in other countries found that
prophylactic cervical cancer vaccination is a cost effective way to
reduce these abnormalities [1]. This study will be used in a cost
effectiveness analysis of prophylactic cervical cancer vaccination
in Ireland. Reference: [1] Goldie SJ, et al. J Natl Cancer Inst
2004;96:604–15.
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OBJECTIVES: The purpose of this study was to estimate the
budget impact on the German health care service of using Hexvix
(hexaminolevulinate) cystoscopy in conjunction with white light
cystoscopy (WLC) in the management of non-invasive bladder
cancer (NIBC). Hexvix cystoscopy potentially allows more com-
plete detection and delineation of bladder cancer tumours com-
pared with standard WLC alone during transurethral resection of
the bladder (TURB). This can potentially lead to fewer tumour
recurrences through more effective tumour resection, and may
change patient management. METHODS: A model was devel-
oped to simulate the ﬂow of newly diagnosed bladder cancer
patients through treatment one year after diagnosis. Model
inputs, including procedure costs and clinical algorithms, are
based on the bladder cancer guidelines by the European Associa-
tion of Urology (EAU), literature review and German clinical
practice. Based on data obtained with an unlicensed and less
readily taken up ﬂuorescent molecule, a relative reduction in
recurrence rate is assumed in the model when compared to WLC.
RESULTS: The model predicts that Hexvix is associated with a
potential reduction in the number of procedures required com-
pared to WLC alone (801 cystectomies and 31,734 TURBs with
Hexvix compared to 881 and 33,823 with WLC alone) in the
ﬁrst year. This is estimated to result in a potential increase in
costs to the German health care system of 5.76% in the ﬁrst year,
compared to WLC alone in all newly diagnosed NIBC patients.
CONCLUSION: The model illustrates how Hexvix, when used
as an adjunct to WLC in TURB may result in the reduction of
invasive, time intensive, high cost procedures such as cystecto-
mies and TURBs, compared with WLC alone. Although the
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